4-chloro-2-fluoro-6-iodophenol | 1192815-08-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 4-chloro-2-fluoro-6-iodophenol
• CAS: 1192815-08-9
• 化学式: C₆H₃ClFIO
• 分子量: 272.445
• InChiKey: SJSWZIGQCMAPBV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-chloro-2-fluoro-6-iodophenol 在 乙基溴化镁 、 溶剂黄146 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 17.0h， 生成 4-chloro-2-fluoro-6-(1H-imidazol-4-yl)phenol
  参考文献：
  名称：

  Discovery of Clinical Candidate (1R,4r)-4-((R)-2-((S)-6-Fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol (Navoximod), a Potent and Selective Inhibitor of Indoleamine 2,3-Dioxygenase 1

  摘要：

  A novel class of 5-substituted 5H-imidazo[5,1-a]isoindoles are described as potent inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1). A structure-based drug design approach was used to elaborate the 5H-imidazo[5,1-a]isoindole core and to improve potency and pharmacological properties. Suitably placed hydrophobic and polar functional groups in the lead molecule allowed improvement of IDO1 inhibitory activity while minimizing off-target liabilities. Structure-activity relationship studies focused on optimizing IDO1 inhibition potency and a pharmacokinetic profile amenable to oral dosing while controlling CYP450 and hERG inhibitory properties.

  DOI：

  10.1021/acs.jmedchem.9b00662
• 作为产物：
  描述：

  4-氯-2-氟苯酚 在 碘 、 potassium iodide 、 sodium hydroxide 作用下， 以 水 为溶剂， 以96%的产率得到4-chloro-2-fluoro-6-iodophenol
  参考文献：
  名称：

  氟化酚的高效可靠碘化和 O-甲基化

  摘要：

  氟化酚类和其他缺电子酚类底物在碱性条件下被碘/碘化物混合物有效且干净地碘化。事实证明，该协议对于生成这种高度氟化的碘酚是最实用的。对于随后在偶联过程中的应用，通常需要保护酚羟基部分。因此，精心设计了实用的碘化和随后的甲基化序列，以提供具有良好至极好产率的高度氟化的苯甲醚。开发的方法适用于广泛的氟化酚类和类似物。

  DOI：

  10.1002/ejoc.201000161

文献信息

• IDO inhibitors
  申请人：NewLink Genetics Corporation

  公开号：US09174942B2

  公开（公告）日：2015-11-03

  Presently provided are compounds according to the formula (I) or (II), and pharmaceutical compositions comprising the compounds, wherein R1, R4, and R5 are defined herein. Such compounds and compositions are useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosuppression associated with an infectious disease.

  目前提供的是按照化学式(I)或(II)提供的化合物以及含有这些化合物的药物组合物，其中R1、R4和R5在此有定义。这些化合物和组合物可用于调节吲哌醇胺2,3-二氧化酶的活性；治疗吲哌醇胺2,3-二氧化酶（IDO）介导的免疫抑制；治疗受益于抑制吲哌醇胺-2,3-二氧化酶酶活性的医疗状况；增强包括给予抗癌剂的抗癌治疗的有效性；治疗与癌症相关的肿瘤特异性免疫抑制；以及治疗与传染性疾病相关的免疫抑制。
• PROCESS FOR SELECTIVELY POLYMERIZING ETHYLENE AND CATALYST THEREFOR
  申请人：Klosin Jerzy

  公开号：US20110282018A1

  公开（公告）日：2011-11-17

  The present invention generally relates to a process that selectively polymerizes ethylene in the presence of an alpha-olefin, and to a metal-ligand complex (precatalyst) and catalyst useful in such processes, and to related compositions. The present invention also generally relates to ligands and intermediates useful for preparing the metal-ligand complex and to processes of their preparation.

  本发明通常涉及在α-烯烃存在的情况下选择性聚合乙烯的过程，以及在这些过程中有用的金属配体复合物（预催化剂）和催化剂，以及相关组合物。本发明还通常涉及用于制备金属配体复合物的配体和中间体，以及它们的制备过程。
• IDO Inhibitors
  申请人：Mautino Mario R.

  公开号：US20110136796A1

  公开（公告）日：2011-06-09

  Presently provided are compounds according to the formula (I) or (II), and pharmaceutical compositions comprising the compounds, wherein R 1 , R 4 , and R 5 are defined herein. Such compounds and compositions are useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine -2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.

  目前提供了按照公式(I)或(II)定义的化合物以及含有这些化合物的药物组合物，其中R1、R4和R5的定义在此处。这些化合物和组合物对于调节吲哚胺2,3-二氧化酶的活性；治疗吲哚胺2,3-二氧化酶(IDO)介导的免疫抑制；治疗从抑制吲哚胺-2,3-二氧化酶的酶活性中获益的医疗状况；增强包括给予抗癌剂的抗癌治疗的有效性；治疗与癌症相关的肿瘤特异性免疫抑制；以及治疗与传染性疾病相关的免疫抑制具有用处。
• Synthesis of Highly Fluorinated 2,2′-Biphenols and 2,2′-Bisanisoles
  作者：Robert Francke、Gregor Schnakenburg、Siegfried R. Waldvogel

  DOI：10.1021/ol101698a

  日期：2010.10.1

  Multiply fluorine-substituted iodo anisoles are efficiently coupled in an Ullmann-type reaction to provide the corresponding bisanisoles. The coupling is selective and even tolerates bromo moieties. Subsequent deprotection of hydroxy groups gives access to highly fluorinated biphenols.
• US8609794B2
  申请人：——

  公开号：US8609794B2

  公开（公告）日：2013-12-17